The Pennant Group is executing an aggressive acquisition-led expansion, with revenue growing 35.8% year-over-year in 2026Q2 and total assets up 73% since 2024Q1.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 4, 2026 | $0.35-2.1% vs $0.36 | $302M+1.0% vs $299M |
Q3 2026 Aug 5, 2026 | $0.36+8.6% vs $0.33 | $298M+3.2% vs $289M |
Q2 2026 May 6, 2026 | $0.32+3.2% vs $0.31 | $285M+1.6% vs $281M |
Q1 2026 Feb 25, 2026 | $0.34+9.7% vs $0.31 | $289M+5.1% vs $275M |
The Pennant Group NASDAQ: PNTG reported third-quarter revenue growth of 32% as acquisitions and higher patient volumes lifted its home health and hospice business, though elevated employee benefits costs and senior living integration challenges pressured margins.
EAGLE, Idaho, Nov. 04, 2026 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, today announced its operating results, reporting GAAP diluted earnings per share of $0.26 for the third quarter of 2026. Pennant also reported adjusted diluted earnings per share of $0.35 for the quarter(1).
EAGLE, Idaho, Nov. 03, 2026 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of operating subsidiaries that provide home health, hospice and senior living services, announced today that it expects to issue its third quarter 2026 financial results on Wednesday, November 4, 2026.
biote (NASDAQ: BTMD - Get Free Report) and The Pennant Group (NASDAQ: PNTG - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings. Risk and Volatility biote has a beta
Benchmark PNTG against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for The Pennant Group, Inc. (PNTG)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $36.36 | $1.26B | 36.88 | 36.31% | 3.05% | 9.04% | — | |
| $124.31 | $2.32B | 20.79 | 23.21% | 7.39% | 9.81% | — | |
| $181.08 | $10.55B | 26.91 | 18.72% | 7.03% | 16.61% | 0.14% | |
| $25.17 | $4.1B | 6.49 | 8.32% | 22.01% | 20.52% | — | |
| $208.85 | $3.26B | 29.08 | 16.94% | 7.24% | 10.35% | 1.18% | |
| $23.20 | $3.03B | -33.73 | 6.24% | -2.63% | -2.59% | — |
The Pennant Group, Inc. (PNTG) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
The Pennant Group, Inc. (PNTG) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
May 20, 2026·SEC
May 6, 2026·SEC
Get notified when PNTG posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
The Pennant Group, Inc. (PNTG) stock FAQ — growth, dividends, profitability & financials explained
The Pennant Group, Inc. (PNTG) reported $1.17B in revenue over the trailing twelve months. Revenue was $947.7M in fiscal year 2025. That is 278% more than the $251.0M of fiscal year 2017.
The Pennant Group, Inc. (PNTG) grew revenue by 38.7% over the trailing twelve months, compared with the twelve months before.
Yes. The Pennant Group, Inc. (PNTG) earned $35.9M in net income over the trailing twelve months (a 3.1% net margin).
The Pennant Group, Inc. (PNTG) had a return on equity (ROE) of 9.0% over the trailing twelve months. That is below the market's typical 10-15%.
The Pennant Group, Inc. (PNTG) generated $25.7M in free cash flow over the trailing twelve months.
